BCL2L1 and Miyoshi myopathy: Meanwhile in MM xenograft models, the co-expression of BCL-xL, Mcl-1 and Bcl-2 were more sensitive to the combination of a selective inhibitor of BCL-xL (A-1331852) but not with venetoclax treatment as compared to monotherapies.